Genomic and Epigenomic alterations after Cancer treatment In Pregnancy.

Genomic and Epigenomic alterations after Cancer treatment In Pregnancy. - GE-CIP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51958

Enrollment

Registered

2021-09-24

Start date

2022-06-13

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemo therapy Pregnancy

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: ancer in pregnancy - CT-treated arm (n=150) • Histological proven cancer during pregnancy (any type and stage) • (Former) participation in part I.IA of the CIP-study S25470 (and I.IB for the placental sub study) • Treatment during pregnancy with one or a combination of the following chemotherapeutic agents: - Cyclophosphamide - Anthracyclines - Taxanes - Platinum derivates • Gestational age (GA) at birth >=24 weeks Cancer in pregnancy - CT-untreated arm (n=150) • No treatment during pregnancy or surgery only (subgroup 1) • Radiotherapy and/or systemic treatment (other than CT) during pregnancy (subgroup 2) • GA at birth >=24 weeks

Exclusion criteria

Exclusion criteria: Exclusion criteria for the three study groups • GA at birth

Design outcomes

Primary

Measure	Time frame
determination of potential (sub)chromosomal alterations and/or changes in DNA methylation in cord blood and buccal cells of the newborn, and the association with chemotherapy concentrations measured in respectively placental or newborn tissue.	—

Countries

Netherlands

Outcome results